CARsgen Therapeutics Announces NDA Acceptance of Satri-cel by China's NMPA
In addition, the company is actively expanding satri-cel application in early-line treatment and perioperative treatment of cancer, including an ongoing Phase Ib registrational trial for pancreatic cancer adjuvant treatment and an ongoing investigator-initiated trial for consolidation treatment following adjuvant therapy in patients with resected G/GEJA.
Professor Lin Shen from Beijing Cancer Hospital, the principal investigator of the CT041-ST-01 clinical trial, said, "Gastric cancer is a malignancy with a substantial global disease burden and significant treatment challenges. For patients with advanced gastric cancer, in particular, existing therapeutic options and their efficacy remain severely limited, resulting in extremely poor survival outcomes. Within the current treatment landscape for gastric cancer, a growing number of patients have experienced failure with immunotherapy and anti-angiogenic therapies. Treatment choices and potential benefits become even more constrained in the third-line setting and beyond. Consequently, there exists a significant unmet clinical need for advanced gastric cancer patients after second-line treatment failure. The confirmatory randomized controlled clinical trial of satri-cel has clearly demonstrated that, compared with existing standard therapies, satri-cel offers significant advantages and clinical value in extending both progression-free survival (PFS) and overall survival (OS). The trial results have garnered widespread international attention and recognition, providing a solid evidentiary foundation for satri-cel's New Drug Application (NDA) submission. We look forward to the approval and market launch of satri-cel, which will offer a new treatment option for the broader population of gastric cancer patients."
Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen Therapeutics, said, "We are delighted to announce that the NDA for our self-developed Claudin18.2-targeted CAR T-cell product satri-cel has been accepted for review by China's NMPA. This marks the world's first CAR T-cell therapy product for solid tumors to reach the NDA stage—a major milestone for the CAR-T field. I extend my sincere gratitude to all clinical investigators, trial coordinators, and patients involved in this program. We are hopeful for its timely approval to provide gastric cancer patients with a new treatment option."
About Satri-cel
Satri-cel is an autologous CAR T-cell product candidate against the protein Claudin18.2 that has the potential to be the first-in-class globally. Satri-cel targets the treatment of Claudin18.2-positive solid tumors with a primary focus on G/GEJA and pancreatic cancer (PC). Initiated trials include investigator-initiated trials (CT041-CG4006, NCT03874897), a confirmatory Phase II clinical trial for advanced G/GEJA in China (CT041-ST-01, NCT04581473), a Phase Ib registrational trial for PC adjuvant therapy in China (CT041-ST-05, NCT05911217), an investigator-initiated trial for satri-cel be used as consolidation treatment following adjuvant therapy in patients with resected G/GEJA (CT041-CG4010, NCT06857786), and a Phase 1b/2 clinical trial for advanced gastric or pancreatic adenocarcinoma in North America (CT041-ST-02, NCT04404595).
Satri-cel has been granted Priority Review by the Center for Drug Evaluation (CDE) of China's NMPA for the treatment of Claudin18.2-positive advanced G/GEJA in patients who have failed at least two prior lines of therapy in May 2025. Satri-cel has been granted Breakthrough Therapy Designation by the CDE of China's NMPA for the treatment of Claudin18.2-positive advanced G/GEJA in patients who have failed at least two prior lines of therapy in March 2025. Satri-cel was granted Regenerative Medicine Advanced Therapy designation by U.S. FDA for the treatment of advanced G/GEJA with Claudin18.2-positive tumors in January 2022. Satri-cel received Orphan Drug designation from the U.S. FDA for the treatment of G/GEJA in September 2020.
About CARsgen Therapeutics Holdings Limited
CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen's mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable.
Forward-looking Statements
All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group's current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group's control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading "Principal Risks and Uncertainties" in our most recent annual report and interim report and other announcements and reports made available on our corporate website, https://www.carsgen.com. No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release.
Contact CARsgenFor more information, please visit https://www.carsgen.com/
View original content to download multimedia:https://www.prnewswire.com/news-releases/carsgen-therapeutics-announces-nda-acceptance-of-satri-cel-by-chinas-nmpa-302491169.html
SOURCE CARsgen Therapeutics
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
22 minutes ago
- Forbes
Singapore Developers Gear Up To Launch Prime Residential Projects Amid Brisk Demand
Developers from City Developments to UOL Group are preparing to launch new luxury residential projects in the coming months amid resilient demand in the city-state despite the property curbs introduced by the government to rein in prices. Sales picked up in July, with developers selling 940 residential units (excluding government-subsidized executive condominiums), up 63% from a year ago, data released by the Urban Redevelopment Authority on Friday showed. While higher taxes continue to deter foreign buyers, Leonard Tay, research head at property consultancy Knight Frank, said he expects demand from Singapore citizens and permanent residents to remain strong. 'New citizens and permanent residents that favor high-rise living will be scouting for opportunities, setting down roots in a stable Singapore against the backdrop of a destabilising global environment,' Tay said by email, noting that Singapore welcomed 23,472 new citizens and 34,491 new permanent residents in 2023. Singapore has also seen an influx of wealthy families in recent years, attracted to the city-state's political stability and business friendly environment. Last year, the number of single family offices in the city-state increased 43% to more than 2,000. After seeing strong demand for prime properties in the central business district, billionaire Kwek Leng Beng's City Developments said it will start marketing the Zyon Grand, a 706-unit twin 62-story residential skyscraper, under construction near the Orchard Road shopping precinct, in the fourth quarter. Part of the mixed-used complex is a 36-story tower with 350 long-stay serviced apartments, retail shops, restaurants and a childcare center on the ground floor. 'The stellar sales performance of several newly launched projects, especially those in prime locations, is expected to boost overall buying sentiment.' Zyon Grand is located near the 524-unit River Green being built by Wing Tai Holdings, which sold 88% of the project during the weekend launch earlier this month. Billionaire Robert Kuok's Allgreen Properties is also developing a condominium in the area, the 596-unit Promenade Peak, which recorded a 54% takeup rate. 'The stellar sales performance of several newly launched projects, especially those in prime locations, is expected to boost overall buying sentiment,' Christine Sun, chief researcher and strategist at property consultancy Realion Group, said by email. 'The increased marketing activity and buying confidence of affluent investors will create a positive ripple effect in the broader market, motivating hesitant buyers or those waiting in the sidelines to invest.' UOL Group—controlled by the family of the late banking and real estate tycoon Wee Cho Yaw—and partner CapitaLand Development plans to start marketing Skye at Holland, a 666-unit residential condominium across two 40-story towers in the upscale Holland Village enclave, this quarter. The company has sold 64% of its 301-unit UpperHouse development on Orchard Boulevard since the July launch. Billionaire Quek Leng Chan's Guocoland is preparing to launch three new projects in the coming months through mid-2026. The Springleaf Residence, a 941-unit development across five towers on Upper Thomson Road in northern Singapore, will be launched this quarter, followed by a project on Faber Walk in the western part of the city-state by the end of the year, according to Guocoland. Guocoland is also developing a 455-unit waterfront condominium on River Valley Road, near the Orchard Road shopping precinct. The project is slated to be launched in the first half of 2026. Projects along the Singapore River have been popular, with Frasers Property—which is controlled by Thai billionaire Charoen Sirivadhanabhakdi and his family—selling 41% of the 348-unit Robertson Opus in July.
Yahoo
24 minutes ago
- Yahoo
Do I need to wear sunscreen indoors? An expert weighs in
Here's what to know about whether you need to use SPF at home, work, or in the car when sun's streaming through the windows. When the sun's out, most of us know the drill: sunglasses on, SPF applied, and try not to burn. But what about when you're indoors? You might have heard claims that we should be wearing sunscreen every single day – even if we're just working from the sofa or sitting in an office. The logic is that UVA rays – linked to premature ageing and some skin cancers – can pass through glass and still reach your skin. But is this true? Some experts aren't convinced, arguing that the amount of UV you get inside is tiny compared with what you're exposed to outdoors. We asked a professor of photobiology to shed light on whether your indoor SPF habit is helping – or just adding another step to your skincare routine. The SPF-indoors debate Much of the advice about wearing sunscreen inside comes from the fact that UVA rays can pass through glass. There are two main types of ultraviolet radiation from the sun that affect our skin: UVA and UVB. UVA has a longer wavelength, can penetrate through glass, and is present at a consistent level throughout daylight hours. It penetrates deeper into the skin and is linked to skin ageing and, over time, some skin cancers. UVB has a shorter wavelength, is blocked by glass, and is strongest in summer and around midday. It's the main cause of sunburn and plays a key role in vitamin D production. But, Brian Diffey, a professor of photobiology and member of the British Association of Dermatologists, says the amount of daylight your skin gets indoors is affected by a number of variables. These include the season, weather, window size and orientation, the reflectiveness of walls and floors, and outside obstructions like buildings or trees that block direct sunlight. He adds that some dermatologists may give broad guidance about wearing sunscreen indoors because they want to keep people aware of the risks of skin damage and cancer, which is vital, but they're not specialists in the physics of light indoors. "Dermatologists are experts in the diagnosis and treatment of skin disease… you wouldn't expect them to know about the physics of sunlight and the transmission through different materials, and how the geometry of a building affects the light levels inside," he tells Yahoo UK. Do we need to wear sunscreen indoors? According to Professor Diffey, for most people, "there is no need to put sunscreen on indoors." "Light levels indoors are orders of magnitude less than they are outdoors," he says, explaining that in his research, he found spending 10 hours in a well-lit indoor space is roughly equivalent, in terms of UVA exposure, to just 10 minutes outside at midday in summer. He encourages people to think about the amount of sky you can see. "When you're outdoors, the whole sky is visible, and that's where much of the UV comes from," he explains. "Indoors, most of this is blocked by roofs, walls and other buildings." If sunlight does stream directly through a window at home or in the office, Professor Diffey says most people will use common sense and move away or close the blinds because of the glare. "If you've got the window shut, you're going to get no UVB and you're going to get very little UVA, unless you're sitting right next to the window," he adds. The exceptions to SPF indoors While Professor Diffey says most people don't need to use sunscreen indoors, he says there are some groups who may benefit. These include: People with skin diseases that make them very sensitive to light People on drugs like isotretinoin (which thins the skin), or on immunosuppressive therapy Some people in certain jobs, like horticulturalists working in greenhouses He stresses this doesn't mean stopping sunscreen altogether, but rather using it where there's a genuine UV risk – not indoors, where levels are minimal. Can you burn in a car? In cars, Professor Diffey says your skin is 'only seeing a small part of the sky because you've got the roof of the car which blocks it.' He adds that UV becomes more hazardous the higher the sun is in the sky – but when the sun is at its highest point (generally between 11am and 3pm), it's blocked by the car roof. "You only get trouble with sunlight in a car in early morning and late evening if you're driving east or west," he continues. "When the sun is troublesome in the middle of the day, it's unlikely you'll get any direct sunlight coming in the car. And so measurements that I and other people have done show typically, inside a car, you might get about 2% on your skin of what you get outside a car." However, if you have your windows open, you may need sunscreen. "If you're driving along and the sun is coming in through the side window and you've got your window open with your arm exposed, driving for several hours, then you can certainly get a sunburn," he says. When do you really need sunscreen? "Obviously, when you're going to be in strong sunshine for an extended period," you need to use sun lotion, says Professor Diffey. Sunsreen is proven to protect against sunburn – its main purpose – and may help reduce premature ageing and skin cancer risk, so we still need to use it to stay safe in the sun. In the UK, that generally means daily use during the sunnier months, especially if you're spending time outdoors. In winter, when UV levels are much lower, everyday SPF is less essential. Many weather apps, including the Met Office and BBC Weather apps, provide localised UV indexes. 'You don't need to use sunscreen when the UV levels are low, which they are indoors, or in the UK winter," he adds. Read more about suncream: The 4 most important things to check on your sunscreen, according to a dermatologist (Yahoo Life UK, 5-min read) The best sunscreen of 2025 – and the two to avoid (Yahoo Life UK, 5-min read) The 8 best sunscreens for kids and adults – and the correct SPF to use for your age (Yahoo Life UK, 7-min read)
Yahoo
41 minutes ago
- Yahoo
Booking.com phishing scam uses secret characters to trick victims - last-minute holiday hunters beware
When you buy through links on our articles, Future and its syndication partners may earn a commission. Cybercriminals are using the Japanese alphabet to spoof Scammers are targeting people with listings on the site Users are advised to carefully review incoming messages Cybercriminals are spoofing with a clever use of Unicode characters in their phishing landing pages to spread malware. Independent security researcher alias JAMESWT recently reported seeing phishing emails being sent to people listing their real estate on the popular lodging reservation service. In the email, the victims are told that someone complained about their listing, and that they should review it fast or face termination. The email also provides the link which when opened, at first glance looks legitimate. However, upon closer inspection, it can be seen in the URL that instead of the forward dash character '/', the link actually uses 'ん' - a Japanese hiragana character representing the sound 'n'. Typosquatting Hiragana is one of the three main scripts used in written Japanese, alongside katakana and kanji. Those that fail to spot the trick and open the site will get served a malicious MSI installer from a CDN link. The researcher added that samples of the malicious site are already available on the cybersecurity platform MalawareBazaar, and that the analysis already shows the infection chain. It is believed that the attackers are spoofing to deliver infostealers and remote access trojans (RAT). Replacing a single character in the URL, in order to trick victims into opening websites, is a long-established practice. It is called 'typosquatting' and banks on the victims not being careful when reviewing the URL they are opening. being one of the most popular lodging reservation services in the world, is often spoofed in such attacks, together with the likes of Amazon, Microsoft, DHL, and others. Defending against these attacks is relatively easy, and requires users to slow down and carefully review incoming communications, especially unsolicited messages. Double-checking links, attachments, websites, and thinking twice about sharing sensitive data is the best course of action these days. Via BleepingComputer You might also like Microsoft warns about a new phishing campaign impersonating Take a look at our guide to the best authenticator app We've rounded up the best password managers Solve the daily Crossword
